Pre-eclampsia primary prevention
Jump to navigation
Jump to search
|
Pre-eclampsia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pre-eclampsia primary prevention On the Web |
|
American Roentgen Ray Society Images of Pre-eclampsia primary prevention |
|
Risk calculators and risk factors for Pre-eclampsia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Zand, M.D.[2]
Overview
- Effective measures for the primary prevention of preeclampsia include administration of low dose aspirin (75-162 mg/day) before the 16th week of pregnancy and calcium supplement(1.2-2.5 g/day), especially in the high risk patients .
Primary prevention
- Effective measures for the primary prevention of preeclampsia include administration of low dose aspirin (75-162 mg/day) before the 16th week of pregnancy and calcium supplement(1.2-2.5 g/day), especially in the high risk patients .[1][2][3]
- In a recent clinical trial, there was 62% reduction in the occurrence of preeclampsia in patients received 150 mg aspirin daily.
- There is not strong evidence about the effectiveness of vitamin C, vitamin E , folic acid , sodium restriction for prevention of preeclampsia.[4][5]
- Low molecular weight heparin is not recommended for prevention of preeclampsia.
Indications of asprin prophylactic use in pregnancy
| Risk level | Risk factors | Recommendation |
| High risk | *Previous preeclampsia
erythematosus, antiphospholipid syndrome) |
Starting low dose of asprin if the patient has one or more of these risk factors |
| Moderate |
sister)
American race, low socioeconomic status)
|
Starting low-dose aspirin if the patient has
two or more of these moderate-risk factors |
| Low risk | Previous uncomplicated full term delivery | NO recommended aspirin |
References
- ↑ Hofmeyr, G Justus; Lawrie, Theresa A; Atallah, Álvaro N; Torloni, Maria Regina (2018). "Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001059.pub5. ISSN 1465-1858.
- ↑ Rolnik, Daniel L.; Wright, David; Poon, Liona C.; O’Gorman, Neil; Syngelaki, Argyro; de Paco Matallana, Catalina; Akolekar, Ranjit; Cicero, Simona; Janga, Deepa; Singh, Mandeep; Molina, Francisca S.; Persico, Nicola; Jani, Jacques C.; Plasencia, Walter; Papaioannou, George; Tenenbau Gavish, Kinneret; Meiri, Hamutal; Gizurarson, Sveinbjorn; Maclagan, Kate; Nicolaides, Kypros H. (2017). "Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia". New England Journal of Medicine. 377 (7): 613–622. doi:10.1056/NEJMoa1704559. ISSN 0028-4793.
- ↑ Mayrink, J.; Costa, M. L.; Cecatti, J. G. (2018). "Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction". The Scientific World Journal. 2018: 1–9. doi:10.1155/2018/6268276. ISSN 2356-6140.
- ↑ Rumbold A, Duley L, Crowther CA, Haslam RR (January 2008). "Antioxidants for preventing pre-eclampsia". Cochrane Database Syst Rev (1): CD004227. doi:10.1002/14651858.CD004227.pub3. PMC 6718237 Check
|pmc=value (help). PMID 18254042. - ↑ Ostadrahimi, Alireza; Mohammad-Alizadeh, Sakineh; Mirgafourvand, Mozhgan; Yaghoubi, Sina; Shahrisa, Elham; Farshbaf-Khalili, Azizeh (2016). "Effects of Fish Oil Supplementation on Gestational Diabetes Mellitus (GDM): A Systematic Review". Iranian Red Crescent Medical Journal. 18 (11). doi:10.5812/ircmj.24690. ISSN 2074-1804.
- ↑ . doi:10.1097/AOG.0000000000003891. Check
|doi=value (help). Missing or empty|title=(help)